Skip to main content
. 2018 Sep 7;13(9):e0203402. doi: 10.1371/journal.pone.0203402

Fig 6. JNK inhibition increases the production of CXCL9 in IFNγ/TNFα-stimulated tumor cells.

Fig 6

The cell lines A) UM-SCC4 and B) UM-SCC47 were stimulated with 1μg/mL rituximab or 1μg/mL cetuximab as indicated for 72h, and the JNK specific inhibitor SP600125 as indicated for 48h, 50IU/mL IFNγ and 30ng/ml TNFα as indicated for 24h. After 48h the concentration of CXCL9 was determined by Enzyme-linked immunosorbent assay in the supernatants P value were determined by unpaired t-tests. Ns: no significance. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.